← board
MCRB
distress 3/10 · well-funded / low risk$5.33+1%today-81% from 52w high
Lead: immune checkpoint related enterocolitis
Revenue
pre-revenue
Liquidity
$30M
Runway
0.7 yrs
Shares 1y
+10%
Price & events
-65.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.9%
1D
+2.9%
1W
-24.4%
1M
-34.1%
3M
-64.6%
6M
-59.3%
1Y
-76.4%
2Y
-96.4%
5Y
-98.9%
All
Overview
- Market Cap
- $51.09M
- Volume
- 5.99K
- 52 Week Range
- $5.11 – $28.63
- Total Shares
- 9.59M
- Float Shares
- 8.47M
- Short %
- 2.13%
- % Held by Insiders
- 11.78%
- % Held by Institutions
- 24.37%
- RVOL
- 0.05x
- Beta
- 0.10
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 11
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- Q2 2026readoutSER-155 · Readout of investigator-sponsored study in irECSEC 8-K
- 2026-06-02partnershipVOWST · Nestlé pays $25M to buy out future VOWST net sales milestones.SEC 8-K
- early 2026readoutSER-155 · Initial efficacy results expected in early 2026 for investigator-sponsored study in irEC.SEC 8-K
- by the end of 2025enrollment completesecondarySER-155 · Enrollment completion anticipated by end of 2025 for investigator-sponsored study evaluating SER-155 in irEC.SEC 8-K
- Q2 2025regulatory submissionFiled (NDA/BLA)SER-155 · Submit draft study protocol to FDASEC 8-K
- May 30 to June 3, 2025conferencedata presentationsecondaryPhase 1SER-155 · Present additional SER-155 clinical results at ASCO 2025SEC 8-K
- 2025-05-01fda agreementSER-155 · Submitted Phase 2 study protocol to FDA for prevention of bloodstream infections in allo-HSCT patients.SEC 8-K
- February 2025conferencedata presentationsecondarySER-155 · SER-155 Phase 1b study results oral presentation at TANDEM Meeting in Best Abstracts in Infectious Diseases.SEC 8-K
- 2024-09-30partnershipVOWST · Closed sale of VOWST microbiome therapeutic business to Nestlé affiliate.SEC 8-K
- 2024-09-30partnershipCompleted sale of VOWST asset to Nestlé Health Science.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $17 (+219% upside) · 2 analysts
- 2026-06-23HC Wainwright & Co.Buy
- 2026-03-13Canaccord GenuityBuy
- 2025-09-24Canaccord GenuityBuy
- 2025-05-08Chardan CapitalBuy → Neutral
- 2025-03-20Chardan CapitalBuy
- 2025-03-14Goldman SachsSell
Competitors — immune checkpoint related enterocolitis
- none identified
Recent news
- 2026-07-21Seres Therapeutics (MCRB) H.C. Wainwright 4th Annual BioConnect Investor Conference summary - Quartr
- 2026-07-10Form 4 Seres Therapeutics Inc For: 10 July By Investing.com - Investing.com Nigeria
- 2026-07-10Seres Therapeutics (MCRB) awards 50,000 stock options to director-officer - Stock Titan
- 2026-07-10Seres Therapeutics (MCRB) awards 6,500 stock options to director Claire Fraser - Stock Titan
- 2026-07-10Seres Therapeutics (MCRB) COO Brady receives 18,750 options vesting quarterly - Stock Titan
- 2026-07-10Seres Therapeutics (MCRB) awards 25,000-share stock option grant to officer Henn - Stock Titan
- 2026-07-10Seres Therapeutics (MCRB) awards 7,500 stock options to officer DesRosier with long vesting - Stock Titan
- 2026-07-10Seres Therapeutics (MCRB) awards director Eric Shaff 6,500 stock options at $7.14 - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.